# Legend Biotech

> Legend Biotech is a commercial-stage cell therapy company best known for CARVYKTI, a personalized BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson. Founded in 2014 and now employing more than 3,200 people, Legend combines discovery, clinical development, manufacturing and commercialization while building experimental autologous, allogeneic and in vivo CAR-T programs for blood cancers and solid tumors.

- **Founded:** 2014
- **Headquarters:** Bridgewater, New Jersey, United States
- **Founders:** Frank Fangliang Zhang (Founder and former CEO)
- **Team size:** More than 3,200 employees as of August 2026
- **Products:** CARVYKTI (ciltacabtagene autoleucel), LB2501, LB2102, LUCAR-G39D, Cell therapy platform
- **Notable:** Developed cilta-cel from early BCMA-directed research into the FDA-approved therapy CARVYKTI in February 2022., Expanded CARVYKTI's U.S. label in April 2024 to eligible patients after at least one prior line of therapy., Treated more than 10,000 clinical and commercial patients with CARVYKTI by the end of 2025.

## Products & services

- **CARVYKTI (ciltacabtagene autoleucel)** — A one-time, BCMA-directed autologous CAR-T therapy for eligible adults with relapsed or refractory multiple myeloma, developed and marketed with Johnson & Johnson.
- **LB2501** — An investigational in vivo CD19/CD20 dual-targeting CAR-T candidate being studied in relapsed or refractory B-cell non-Hodgkin lymphoma.
- **LB2102** — An investigational DLL3-targeted autologous CAR-T candidate for small-cell lung cancer and large-cell neuroendocrine carcinoma, licensed globally to Novartis subject to Legend conducting the U.S. Phase 1 trial.
- **LUCAR-G39D** — An investigational allogeneic CAR-T candidate being evaluated for B-cell non-Hodgkin lymphoma.
- **Cell therapy platform** — Discovery, clinical development, manufacturing and commercialization capabilities spanning autologous, allogeneic and in vivo cell therapy approaches.

## Achievements

- Developed cilta-cel from early BCMA-directed research into the FDA-approved therapy CARVYKTI in February 2022.
- Expanded CARVYKTI's U.S. label in April 2024 to eligible patients after at least one prior line of therapy.
- Treated more than 10,000 clinical and commercial patients with CARVYKTI by the end of 2025.
- Reached approximately $1.9 billion in CARVYKTI net trade sales in 2025 and achieved full-year franchise profitability.
- Expanded CARVYKTI availability to 348 sites across 19 markets by August 2026.
- Expanded the Raritan site into a facility capable of supporting treatment for up to 10,000 patients annually.
- Reported first clinical proof-of-concept data for its in vivo CAR-T candidate LB2501 in June 2026.
- Closed a 2020 Nasdaq IPO with approximately $487.3 million in gross proceeds.

## Latest updates

- **2026-08** — Reported second-quarter revenue of $387.5 million, operating income of $57.7 million and CARVYKTI net trade sales of approximately $657 million.
- **2026-08** — CARVYKTI reached 348 treatment sites in 19 markets following its launch in Ireland.
- **2026-07** — Ying Huang stepped down as CEO and director; CARVYKTI business president Alan Bash became interim CEO while the board began a search.
- **2026-06** — Reported early Phase 1 proof-of-concept data for in vivo CAR-T candidate LB2501 in a small cohort of patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- **2026-06** — Closed a public offering of 7.7 million ADSs for approximately $212 million in net proceeds.
- **2026-06** — Presented first-in-human LB2102 data in small-cell lung cancer and large-cell neuroendocrine carcinoma at ASCO 2026.

## Links

- Website: https://legendbiotech.com
- LinkedIn: https://www.linkedin.com/company/legendbiotechco.
- Twitter/X: https://x.com/legendbiotech
- Instagram: https://www.instagram.com/legend_biotech/

---

Profile page: https://yespress.io/legend-biotech
Published by YesPress — https://yespress.io
Last updated: 2026-08-12